# WEE1 dependency and drugs in one query

> WEE1 is a DepMap common-essential gene (1178 of 1178 cell lines dependent); one BioQ query adds drugs, disease evidence, expression and pathways.

Data as of 2026-11-06 · Published 2026-11-10 · Updated 2026-11-06 · https://bioq.bio/blog/en/gene-wee1-profile

![BioQ results page for the query WEE1 showing CRISPR dependency, drug, disease evidence, expression and pathway blocks side by side.](https://bioq.bio/blog/img/gene-wee1-profile/en/hero.webp)

Read together, WEE1 dependency and drugs give a consistent picture: the knockout reduced viability in all 1178 of 1178 DepMap cell lines (mean Chronos gene effect -2.455), and 4 drugs are linked to the gene, led by azenosertib at PHASE_3 and adavosertib at PHASE_2. Disease evidence is less uniform. The data are as of 2026-11-06.

## What we asked

We wanted one view of WEE1 across the layers a target review usually needs: how much cell lines depend on it, which drugs act on it and how potent they are, which diseases the evidence points to, whether tumours express more of it than normal tissue, and where it sits in pathways and interaction networks. The query was the gene symbol alone: WEE1.

The question behind it is practical. Before spending time on a target, you want to know which of these facts agree with each other and which pull in different directions.

## What BioQ returned for WEE1 dependency and drugs

BioQ ran 7 engine queries against 7 distinct resources in 0.51 engine seconds in total. Doing the same by hand would mean opening DepMap, ChEMBL, Open Targets, ClinicalTrials.gov, TCGA/GTEx, CIViC, Reactome and STRING separately and reconciling gene identifiers across them. The three blocks below carry the main findings.

**CRISPR dependency (DepMap Chronos, release depmap_24q4).** All 1178 cell lines count as dependent, which is 100.0 percent, and the gene is flagged common essential. The eight lineages shown are the most negative by mean gene effect.

| Lineage | Cell lines | Dependent | % dependent | Mean gene effect |
|---|---|---|---|---|
| Bone | 46 | 46 | 100 | -2.623 |
| Thyroid | 11 | 11 | 100 | -2.597 |
| Kidney | 34 | 34 | 100 | -2.562 |
| Skin | 74 | 74 | 100 | -2.549 |
| Peripheral Nervous System | 44 | 44 | 100 | -2.54 |
| Bladder/Urinary Tract | 34 | 34 | 100 | -2.537 |
| Ovary/Fallopian Tube | 59 | 59 | 100 | -2.5 |
| Lymphoid | 93 | 93 | 100 | -2.494 |

![BioQ DepMap block for WEE1 listing Chronos gene effect by lineage, with every lineage at 100.0 percent dependent](https://bioq.bio/blog/img/gene-wee1-profile/en/dep.webp)
*DepMap block for WEE1 as shown in BioQ, release depmap_24q4.*

**Drugs by clinical stage.** Open Targets, ChEMBL, the Drug Repurposing Hub and ClinicalTrials.gov together list 4 drugs. The potency column shows the exact pChEMBL value (the negative log10 of the molar potency, so higher means stronger) and the assay type it comes from.

| Drug | Max clinical stage | Mechanism | Best exact pChEMBL | Type | Trials by name |
|---|---|---|---|---|---|
| Azenosertib | PHASE_3 | Serine/threonine-protein kinase WEE1 inhibitor | 8.89 | IC50 | 11 |
| Adavosertib | PHASE_2 | Serine/threonine-protein kinase WEE1 inhibitor | 9.25 | IC50 | 25 |
| Pd-0166285 | UNKNOWN | — | 9.3 | KI | 0 |
| Pd-407824 | UNKNOWN | — | — | — | 0 |

**Disease association (Open Targets).** The gene has associations with 1113 diseases. The six highest-scoring are shown.

| Disease | Association score | Evidence items |
|---|---|---|
| neurodegenerative disease | 0.519 | 105 |
| actinic keratosis | 0.439 | 4 |
| squamous cell carcinoma | 0.419 | 36 |
| cutaneous squamous cell carcinoma | 0.415 | 4 |
| sitting height measurement | 0.386 | 3 |
| autoimmune disorder of central nervous system | 0.379 | 3 |

The other layers are shorter. TCGA/GTEx Toil data allow a tumour-versus-normal comparison in 24 cancer types. Glioblastoma Multiforme stands out: mean tumour expression is 10.73 against 6.71 in normals (153 tumours, 5 normals), with a log2 fold of 0.68. The next five cancer types shown, Kidney Chromophobe, Kidney Papillary Cell Carcinoma, Bladder Urothelial Carcinoma, Liver Hepatocellular Carcinoma and Cholangiocarcinoma, all have negative log2 fold values, from -0.27 to -0.12.

CIViC holds 1 record: the profile WEE1 RS3910384 in Lung Non-small Cell Carcinoma, with Platinum Compound and Gemcitabine, evidence level B, significance Sensitivity/Response. Reactome maps WEE1 to 18 pathways; the most specific is G2/M DNA replication checkpoint (R-HSA-69478, 7 genes). STRING v12 reports 1373 interaction partners, and the top scores are CDK1 (998), PLK1 (992), CHEK1 (992), CCNB1 (990), CDK2 (987) and CDC25A (956).

## What it means and how to read it

Three facts are worth checking before the rest.

1. **The dependency is broad, not selective.** With every line dependent and the gene flagged common essential, DepMap does not separate sensitive from insensitive lineages. The lineage ranking (Bone at -2.623 down to Lymphoid at -2.494 among those shown) is a narrow spread. Note also that "dependent" is defined by a fixed Chronos cut-off chosen by the pipeline, not by the data themselves. For a target such as WEE1, this layer says the gene matters for cell viability in culture. It does not say where a drug window might exist.

2. **The drug layer is populated, and the potency values are high but of mixed type.** Adavosertib shows an exact IC50-based pChEMBL of 9.25 and 25 trials found by name. Azenosertib shows 8.89 (IC50) and 11 trials. Pd-0166285 has 9.3, but that value comes from a Ki, so it should not be compared directly with the IC50 figures. Pd-407824 has no exact value and no trials by name, and both Pd compounds carry the stage UNKNOWN. The trial counts are matches by drug name, not a curated list of studies.

3. **Disease evidence and expression do not line up with the dependency.** The top Open Targets association is neurodegenerative disease (score 0.519, 105 evidence items), ahead of squamous cell carcinoma (0.419, 36 items). Actinic keratosis (0.439, 4 items) and cutaneous squamous cell carcinoma (0.415, 4 items) also rank high. Association scores combine evidence types and do not by themselves indicate direction of effect or druggability. In TCGA/GTEx, only Glioblastoma Multiforme of the six shown has higher expression in tumour, while the other five are lower. Dependency in cell lines, genetic or literature association, and bulk mRNA level in tissue are three different questions, and here they give three different answers.

The pathway and interaction layers agree with each other and with the drug mechanism. The Reactome entries are cell-cycle checkpoint pathways, and the strongest STRING partners (CDK1, PLK1, CHEK1, CCNB1, CDK2, CDC25A) are cell-cycle regulators. That fits the annotated mechanism as a serine/threonine-protein kinase WEE1 inhibitor.

## How to reproduce it in BioQ

1. Open BioQ and make sure the query box is empty.
2. Enter the gene symbol exactly as below.

```text
WEE1
```

[Open this query in BioQ](https://bioq.bio/login?next=%2Fapp%23q%3DWEE1)

3. Wait for the blocks to load. Each one names its source and release (for example depmap_24q4 for the dependency block).
4. Start with the DepMap and drug blocks, then compare them with the Open Targets and TCGA blocks.
5. Note the data date shown with the answer, since the layers update on different schedules.

## Limits: what the data do not show

- Cell-line CRISPR data do not show tolerability in normal tissue or in patients. A common-essential flag is a property of cultured lines.
- Nothing here ranks which tumour types would respond to a WEE1 inhibitor. The 100.0 percent dependency leaves no contrast to rank on.
- pChEMBL values come from different assays and different types (IC50, Ki). They describe potency in vitro, not selectivity or clinical activity.
- Clinical stage labels and trial counts come from name matching across sources. They do not state trial outcomes.
- The single CIViC record concerns a variant and platinum plus gemcitabine in lung cancer. It is not evidence about WEE1 inhibitors.
- Open Targets scores summarise evidence volume and type, not the direction of the biology. The neurodegenerative disease signal in particular cannot be interpreted from the score alone.
- TCGA/GTEx comparisons use unequal group sizes, such as 5 normals for Glioblastoma Multiforme, and bulk RNA does not reflect protein activity or the phosphorylation state of CDK1.

## Data and method
The numbers on this page were read from the BioQ engine on 2026-11-06 (7 queries, 0.5 s of engine time in total). The tables are generated by code from the engine's answers; the text only restates them.

`/civic`, `/depmap`, `/drugs`, `/interaction`, `/ot_association`, `/pathway`, `/tcga`

Run the same query yourself: [WEE1](https://bioq.bio/login?next=%2Fapp%23q%3DWEE1)

*For research use only. This page summarises public data and is not medical advice.*

BioQ is an AI search engine and agent with one goal: making biology research 100X faster. Ask in the web app, over the REST API, or from Claude, ChatGPT or Cursor through MCP.

## Queries used

- [`WEE1`](https://bioq.bio/login?next=%2Fapp%23q%3DWEE1)

## Frequently asked questions

### Is WEE1 a common essential gene in DepMap?

Yes. In DepMap release depmap_24q4, all 1178 of 1178 cell lines are classed as dependent, and the mean Chronos gene effect is -2.455. The gene is flagged common essential.

### Which WEE1 inhibitors are listed and at what stage?

BioQ lists 4 drugs for WEE1. Azenosertib is at PHASE_3 and adavosertib at PHASE_2. Pd-0166285 and Pd-407824 have the stage UNKNOWN.

### How potent are adavosertib and azenosertib in ChEMBL?

The exact pChEMBL for adavosertib is 9.25 and for azenosertib 8.89, both from IC50 measurements. Higher means stronger, and these are in vitro potency values only.

### Which disease does Open Targets associate most with WEE1?

Neurodegenerative disease scores highest at 0.519 with 105 evidence items, out of 1113 associated diseases. Squamous cell carcinoma follows among those shown at 0.419 with 36 evidence items.

### Is WEE1 expressed higher in tumours than in normal tissue?

It depends on the cancer type. Among the six types shown from 24 with both tumour and normal data, only Glioblastoma Multiforme is higher in tumour (10.73 against 6.71). The other five have negative log2 fold values.

## Sources

- Dataset: [DepMap CRISPR Chronos gene effect (24Q4)](https://depmap.org/portal/)
- Dataset: [Open Targets Platform; ChEMBL; Drug Repurposing Hub](https://platform.opentargets.org/)
- Dataset: [TCGA pan-cancer expression (UCSC Xena Toil recompute)](https://xenabrowser.net/)
- Dataset: [CIViC: Clinical Interpretation of Variants in Cancer](https://civicdb.org/)
- Dataset: [Reactome pathway knowledgebase](https://reactome.org/)
- Dataset: [STRING v12 protein-protein interactions](https://string-db.org/)

> Results come from public databases as of the date shown and may change. BioQ gives research information, not medical advice.
